After pausing for several years due to the COVID-19 pandemic, the 2023 edition of Aerosol School will take place virtually. Students will have access to more than 200 hours of lectures from well-known experts on topics ranging from the basics of aerosol delivery devices to hot topics such as the delivery of macrophages and monoclonal antibodies via inhalation. … [Read more...] about Aerosol School goes virtual for 2023
News
Pneumagen raises £8 million for Phase 2 trial of Neumafil nasal spray in COPD patients
Pneumagen said that it has closed an £8 million funding round, with proceeds going to support Phase 2 development of the company's Neumifil multivalent carbohydrate binding module (mCBM) nasal spray, including a Phase 2b trial in COPD patients experiencing exacerbations caused by viral infection that is expected to be initiated in 2024. The company announced in … [Read more...] about Pneumagen raises £8 million for Phase 2 trial of Neumafil nasal spray in COPD patients
Nephron Pharmaceuticals announces availability of albuterol sulfate inhalation solution in 25mg/5ml vials
Nephron Pharmaceuticals announced that the company is now offering 0.5% albuterol sulfate inhalation solution in 5 ml vials for direct shipping to US medical facilities in response to a nationwide shortage. Ritedose Pharmaceuticals recently announced that if would begin manufacturing 0.5% albuterol in response to the shortage. Nephron notes that has been manufacturing … [Read more...] about Nephron Pharmaceuticals announces availability of albuterol sulfate inhalation solution in 25mg/5ml vials
Pulmotect gets $8.9 million grant for Phase 2 trial of PUL-042 inhalation solution
The Cancer Prevention and Research Institute of Texas (CPRIT) has awarded an $8.9 million grant to Pulmotect for continued development of the company's PUL-042 immune stimulating inhalation solution, the company announced. Pulmotect said that the funds will go toward a Phase 2 trial titled, “A Phase 2 Multiple Dose Study to Evaluate the Efficacy and Safety of PUL-042 … [Read more...] about Pulmotect gets $8.9 million grant for Phase 2 trial of PUL-042 inhalation solution
Health Canada approves Lupin’s generic of Spiriva tiotropium bromide DPI
According to Lupin, Health Canada has approved the company's generic version of Boehringer Ingelheim's Spiriva tiotropium bromide inhalation powder for the treatment of COPD. In the UK, the MHRA approved the company's Lutio tiotropium DPI for the treatment of COPD in August 2022. Lupin President, Legal, for Canada, Australia, and Japan, Sofia Mumtaz commented, … [Read more...] about Health Canada approves Lupin’s generic of Spiriva tiotropium bromide DPI
Altamira says trial of Bentrio bentonite-based nasal spray for SAR met its primary endpoint
Altamira Therapeutics announced that the NASAR trial comparing its Bentrio bentonite-based gel nasal spray to saline nasal spray in patients with seasonal allergic rhinitis met its primary endpoint, demonstrating a statistically significant reduction in nasal allergy symptoms. The OTC nasal spray is currently available in Germany and has received 510(k) clearance in … [Read more...] about Altamira says trial of Bentrio bentonite-based nasal spray for SAR met its primary endpoint
MannKind names Burkhard Blank as Executive VP, R&D, and Chief Medical Officer
Inhaled drug developer MannKind Corporation has announced the appointment of former Acorda Therapeutics Head of R&D and Chief Medical Officer Burkhard Blank as MannKind's new Executive VP, Research & Development, and Chief Medical Officer. At Acorda, he was responsible for Phase 3 development of Inbrija levodopa inhalation powder. Blank was most recently Head … [Read more...] about MannKind names Burkhard Blank as Executive VP, R&D, and Chief Medical Officer
Aerami says it will advance AER-901 inhaled imatinib into a Phase 2 trial for PAH and PH-ILD
Aerami Therapeutics said that pre-clinical and Phase 1 data presented recently at ATS support advancing the company's AER-901 nebulized imatinib into a Phase 2 trial that will include both patients with pulmonary arterial hypertension (PAH) and patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company said that it expects to … [Read more...] about Aerami says it will advance AER-901 inhaled imatinib into a Phase 2 trial for PAH and PH-ILD
Copley Scientific hires Clair Brooks as Applications Specialist
Inhaler testing equipment maker Copley Scientific has announced the appointment of Clair Brooks as Applications Specialist "to maintain a customer-centric focus as growth continues." Brooks was most recently a field application specialist at Primerdesign, a maker of PCR kits. Copley Managing Director Jamie Clayton commented, "The role of applications specialist … [Read more...] about Copley Scientific hires Clair Brooks as Applications Specialist
Ceapro presents pre-clinical data from study of inhalable yeast beta glucan
Ceapro has presented results from a pre-clinical study of inhalable yeast beta glucans processed with the company's pressurized gas expanded (PGX) technology at ATS, the company said. The study, which was conducted in collaboration with McMaster University, evaluated the aerosolization characteristics of inhaled PGX-processed yeast beta glucans (PGX-YBG) and the … [Read more...] about Ceapro presents pre-clinical data from study of inhalable yeast beta glucan